KMDA

Kamada

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

County of HQ

Israel

Next Earnings Date

05/13/26

Business Summary

Kamada operates as a specialty and generic drug manufacturer, generating revenue through the development, production, and commercialization of plasma-derived and other niche pharmaceutical products. Its cash generation relies on maintaining regulatory approvals, scaling manufacturing efficiently, and monetizing specialty therapeutics in targeted markets. The moat is built less on blockbuster dominance and more on specialized production capabilities, regulatory know-how, and established distribution relationships. While not an unassailable franchise, its stability stems from operating in defensible therapeutic niches that require technical expertise and compliance infrastructure, limiting casual competition.

 


Analyze KMDA on TradingView

VALUATION

P/E

24.3

Market Cap ($M USD)

$478

Forward P/E

14.3

PEG

4.2

PRICE TO SALES

2.7

PRICE TO BOOK

1.8

EV / EBITDA

10.6

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

2.90%

Annual Payout

$0.25

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$0.35

Next Year EPS Growth Estimate

$0.59

Next Year Revenue Growth Estimate

9.80%

Return on Equity (ROE)

7.50%

FREE CASH FLOW

Operating Margin

14.50%

Debt-to-Equity

0

Piotroski F-Score

6

Altman Z-Score

3.7

Return on Invested Capital (ROIC)

7.00%

Current Ratio

4.1

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze KMDA on TradingView

Gainseekers Quantitative Analysis

Summary

At 24.3x earnings with a Forward P/E of 14.3, the market is clearly pricing in a material earnings acceleration, yet the PEG Forward of 4.2 suggests that growth expectations may already be stretched relative to fundamentals. A Market Cap of $478M against a Price/Sales of 2.7 and Price/Book of 1.8 places the stock in a reasonable valuation band for a specialty pharma name, but not an obvious deep-value outlier. The Altman Z-Score of 3.7 signals low bankruptcy risk and balance sheet stability, reinforced by a strong Current Ratio of 4.1, so financial distress is not the issue here. This is not a broken company — it’s a stable but modestly profitable operator that the market may be cautiously discounting due to growth quality rather than solvency concerns.

AI Exposure / Tech Reliance

As a Drug Manufacturers - Specialty & Generic company in Healthcare, its AI exposure is indirect, largely through R&D efficiency, regulatory data analysis, and manufacturing optimization. The sector benefits from digitalization in clinical data management and supply chain automation, which can support margin expansion over time. However, AI is unlikely to radically alter its competitive positioning in the near term, making it more operationally than technologically leveraged.

The Bull Case

A GARP investor could justify ownership based on financial stability and improving earnings optics. The Forward P/E of 14.3 against a current P/E of 24.3 implies anticipated earnings expansion, and with ROIC at 7.00% and ROE at 9.80%, capital is being deployed above minimal thresholds of efficiency, though not spectacularly. The Operating Margin of 7.50% demonstrates positive operating leverage in a notoriously margin-sensitive industry, and a Piotroski F-Score of 6 signals fundamentally stable conditions rather than deterioration. Add in a conservative Debt/Equity of 14.50% and a strong Current Ratio of 4.1, and you have a balance sheet that can support continued operations and selective growth without financial strain. For institutions seeking small-cap healthcare exposure with manageable risk metrics and a solid Altman Z-Score of 3.7, this presents as a controlled, moderately undervalued earnings transition story.

The Bear Case

The red flag is growth quality. A PEG Forward of 4.2 is expensive by any GARP standard, implying that expected growth does not justify even the reduced Forward P/E of 14.3. Operating Margin of 7.50% and ROIC of 7.00% are merely average, not high enough to signal durable competitive advantages or pricing power. Institutional Ownership at $13.00 (as provided) is not overwhelmingly supportive, and with TTM Yield at 0 and a Dividend 5-Year Avg of 0, income investors have no cushion. If earnings estimates falter, the valuation compression from 24.3x toward a lower multiple could be swift, especially in a sector where pipeline or regulatory risk can quickly impair sentiment.

Market Sentiment & Smart Money

Short Interest %

0.50%

Analyst Consensus

1.8

Average Analyst Price Target

$13.00

Institutional Ownership %

48.90%

1-Year Beta

1.07

Insider Buying % (6 Mo)

7.20%%

Distance to 52-Week High

90.80%

Distance to 52-Week Low

146.90%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.